Dexcom Inc (DXCM) is overvalued and GE HealthCare Technologies Inc (GEHC) is undervalued.
Against our estimates of intrinsic value, GEHC trades at the wider discount: a margin of safety of +29%, against -61% for DXCM.
Values as of the 22 Sept 2026 close.
Discounting its cash flows at 11.4% (average of 3 methods) values the shares at $55.75; the price of $89.53 is 61% above that value, and 70% of that value comes from beyond year five.
Leak Score 68/100 on 9 of 12 signals
Discounting its cash flows at 9.1% (average of 3 methods) values the shares at $93.41; the price of $66.27 is 29% below that value, and 75% of that value comes from beyond year five.
Leak Score 63/100 on 5 of 12 signals
| Metric | DXCM | GEHC |
|---|---|---|
| Verdict | Overvalued | Undervalued |
| Price | $89.53 | $66.27 |
| Intrinsic value | $55.75 | $93.41 |
| Margin of safety | -61% | +29% |
| Leak Score | 68/100 (9/12) | 63/100 (5/12) |
| Market cap | $33.8B | $29.9B |
| Revenue growth, 5 years | 19.3% | 3.7% |
| Operating margin | 22.9% | 13.7% |
| Net margin | 20.1% | 9.3% |
| Return on equity | 38.5% | 19.2% |
| Debt to equity | 0.53 | 0.96 |
| P/E | 35.3x | 15.2x |
| Forward P/E | 28.7x | 12.2x |
| P/B | 12.9x | 2.7x |
| Dividend yield | — | 0.2% |